Replies to post #138466 on Biotech Values

[mcbio]

The panel at Cowen pointed to TMC435 as the drug in this class to watch, with something from Merck (forget the designation) as the runner-up.

Great to hear. Thanks Peter. Let's see how those initial TMC435+7977 combo results turn out later this year.

[DewDiligence]

The MRK drug in question is MK-7009, a protease inhibitor (#msg-47224801).